S&P/ASX 200 Stages a Comeback: Banks Hold Strong, Healthcare and Materials Feel the Squeeze

It was one of those Fridays that keeps you on your toes. The S&P/ASX 200 looked like it was headed for a bloodbath early on, dipping below 8,905—but buyers stepped in, and we closed the session at 8,960.60. That’s a drop of just 0.14%. Considering where we started the day, I’d call that a win.

We’ve seen this play out before. The local market snapped a three-session winning streak, but the fact that we cut those morning losses in half tells you everything about the underlying support. The volatility we’re seeing is purely external. But let’s get into the details, because the sectors are telling very different stories right now.

The Big Four hold the line

If you want to know why the ASX didn’t get completely wiped out today, look no further than the banking sector. The S&P/ASX 200 Financials [XFJ] proved exactly why it’s the anchor of this market. While tech and miners were getting hammered, the money printers just kept humming.

Specifically, the S&P/ASX 200 BANKS [XBK] index had a stellar session. National Australia Bank, Westpac, and CBA all finished in the green—modest gains, sure, up between 0.1% and 0.2%—but green is gold on a red day. ANZ was the odd one out, slipping a fraction, but the resilience was unmistakable. Investors are parking their cash in financials as a safe harbor, and honestly, with dividend season looming, I don’t blame them.

• Defensive flows: Money rotated out of growth stocks and straight into the Big Four.
• Volume: Trading volume in financials was well above the monthly average.
• Outlook: With rate expectations settling, the net interest margin outlook is stabilizing.

Healthcare takes a hit, but value hunters are circling

It wasn’t such a pretty picture for the med-techs and biotechs. The S&P/ASX 200 Health Care [XHJ] has had a rough run in 2026, and today added to the pain. The index is now down nearly 17% year to date. That’s a brutal correction for a sector we usually call defensive.

But here’s where it gets interesting. In the middle of the sell-off, I was watching Telix Pharmaceuticals. This stock has been on a rollercoaster. Down 48% over the last year, but up 55% since mid-February. Today, it was one of the top gainers on the entire ASX 200, jumping nearly 7% to $14.57. Some local brokers are still calling a $19 price target. That’s a 39% upside from here.

Same story with Mayne Pharma. The stock is down 32% on the year, but the company came out swinging today, telling the market that new tariff noise will have "no material impact" on FY27 earnings. When you see a stock trading at $2.16 with an average analyst target of $5.75, you have to sit up and pay attention. The XHJ might be bleeding, but the vultures are circling for a reason.

Materials feel the weight of the world

If healthcare was bad, the miners were worse. The S&P/ASX 200 Materials [XMJ] got absolutely hammered. We’re talking a sea of red from BHP down to the small caps. BHP edged down 0.4%, but the real pain was in the mid-tiers. Fortescue dropped nearly 2%, and Mineral Resources wasn’t far behind.

It’s the same old story—commodity prices are twitchy, and global growth fears are spooking the market. The XMJ has been incredibly volatile all quarter, and today’s price action suggests institutional investors are still reducing risk. Champion Iron lost over 4%, and the gold miners, which usually act as a hedge, were also underwater. Evolution Mining lost 2%. When gold doesn’t work on a risk-off day, you know sentiment is fragile.

Looking at the broader market, the tech sell-off added to the misery. Xero slipped almost 3%, and WiseTech dropped more than 2%. Even the oil stocks, which should be flying with crude where it is, were mostly lower. Woodside and Santos both declined.

So, where does that leave us? The S&P/ASX 200 is showing incredible grit. We bounced hard off the intraday lows. The banks are holding the fort, and while healthcare and materials are under pressure, the value propositions are starting to scream. It’s a stock picker’s market, pure and simple. Don’t just buy the index; buy the stories that make sense.